The United States and United Kingdom Agree to Duty-Free Deal on Pharmaceuticals.

Britain and America have secured a major commercial pact that will preserve zero tariffs on UK medicine exports going into the US market.

The Terms of the Pact

Under the terms of the agreement, the UK has pledged to raise spending on pharmaceuticals through the public health system. This move guarantees that tariffs on these crucial goods will remain at zero for a timeframe of the next three years.

This agreement is in response to earlier statements to dramatically increase import taxes on patented drug products, with potential rates mentioned reaching 100%.

"This arrangement between the United Kingdom reinforces the international landscape for innovative medicines and brings long-overdue equity to American-British drug exports," an announcement noted.

Economic Importance

Medicines are one of the UK's biggest export categories to the US, which is easily the largest buyer for major companies like GSK and AstraZeneca.

Statistics indicate that in the one-year period prior to September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This amount represented nearly one-fifth of all goods exports in that period.

"This agreement secures employment, stimulates investment and facilitates the UK to become a worldwide center for medical research," a government official remarked.

Specific NHS Changes

The agreement includes several specific commitments from the UK:

• Revised Affordability Limit: The UK will raise the price threshold at which it deems new therapies to be unaffordable by 25%.
• Higher Drug Budget: There is a target to increase total public funding on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
• Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be restricted at fifteen percent. Previously, refunds exceeded 20%.

Industry Background

This agreement follows a protracted tension between the drug companies and the British authorities over spending levels and regulatory access.

The disagreement were exacerbated by arguments that US customers were paying a premium for the equivalent treatments than patients in the Britain and the EU.

Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.

One official acknowledged that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.